Benign Blood Disorders GCC Nursing Guide

Haematology clinical reference — anaemia, sickle cell, thalassaemia, haemostasis, thrombophilia

← Back to Index
Scope note: This guide covers benign haematological conditions. For malignant haematology and bone marrow transplant, see gcc-nurse-haematology-oncology-guide.html.

Anaemia Classification by MCV

Microcytic (MCV <80 fL)

Iron deficiency anaemia (most common worldwide), Thalassaemia (alpha/beta), Sideroblastic anaemia, Anaemia of chronic disease (some)

Normocytic (MCV 80–100 fL)

Anaemia of chronic disease, Haemolytic anaemia, Aplastic anaemia, Acute blood loss, Renal anaemia (EPO deficiency)

Macrocytic (MCV >100 fL)

Vitamin B12 deficiency, Folate deficiency, Liver disease, Hypothyroidism, Alcohol excess, Drugs (methotrexate, hydroxyurea)

Key Diagnostic Parameters

TestIDAACDThalassaemia TraitB12/Folate Def.
MCVLowNormal/LowLow (very low MCV)High
Ferritin<15 µg/LNormal/HighNormalNormal
Transferrin sat.<16%LowNormalNormal
ReticulocytesLowLowNormal/slightly raisedLow (megaloblastic)
Serum ironLowLowNormalNormal
TIBCHighLow/NormalNormalNormal

Iron Deficiency Anaemia (IDA)

Diagnostic Criteria

  • Ferritin <15 µg/L (diagnostic for IDA)
  • Ferritin 15–30 µg/L — possible IDA (check transferrin saturation)
  • Transferrin saturation <16%
  • Hypochromic, microcytic red cells on film

Common Causes in GCC

  • Dietary deficiency (restricted diet, vegetarian/vegan)
  • Menorrhagia — very common, especially among female expats
  • Pregnancy and lactation
  • GI blood loss (peptic ulcer, hookworm)
  • Malabsorption (coeliac, post-gastrectomy)

Oral Iron Therapy

Administration tips:

Take on empty stomach or with vitamin C (orange juice). Avoid within 2h of tea, dairy, calcium supplements, antacids, PPIs. Ferrous sulfate 200mg TDS or ferrous fumarate 210mg BD. Expect black stools — counsel patient. Continue for 3 months after Hgb normalises to replenish stores.

IV Iron — Ferric Carboxymaltose

Pre-infusion: Check allergy history; resuscitation equipment available.
During: Observe for 30 min post-infusion — anaphylaxis risk (rare but serious).
Signs of reaction: Urticaria, hypotension, bronchospasm, facial flushing.
Post-infusion: Transient hypophosphataemia possible; recheck ferritin at 4–6 weeks.

B12 & Folate Deficiency

Vitamin B12 Deficiency

  • Causes: Pernicious anaemia (autoimmune — anti-IF antibody), vegans, gastric surgery, ileal disease, metformin long-term
  • Neurological features: subacute combined degeneration (paraesthesia, gait instability, cognitive impairment) — may occur without anaemia
  • Investigations: Serum B12 (low), MMA elevated, homocysteine elevated
Treatment — Pernicious Anaemia/Malabsorption:

IM hydroxocobalamin 1mg alternate days × 2 weeks, then every 3 months lifelong. Oral cyanocobalamin only if dietary cause and no malabsorption. Monitor serum K+ after starting treatment — hypokalaemia risk as marrow recovers.

Folate Deficiency

  • Causes: Poor diet, malabsorption, pregnancy, haemolysis, methotrexate, anticonvulsants
  • Exclude B12 deficiency before giving folate alone — may unmask B12 neuropathy
Treatment: Oral folic acid 5mg daily × 4 months. Prevention in pregnancy: folic acid 400 mcg daily from pre-conception to 12 weeks; 5mg daily if high-risk (previous neural tube defect, haemolytic anaemia, anti-epileptics).

Anaemia of Chronic Disease (ACD)

Pathophysiology

Driven by chronic inflammation → elevated hepcidin → blocks iron release from macrophages and intestinal absorption → functional iron deficiency despite adequate iron stores.

  • Common underlying conditions: CKD, rheumatoid arthritis, IBD, HIV, malignancy, chronic infections
  • Typically normocytic (can be microcytic)
  • Ferritin normal or elevated (acute phase protein)

Management

  • Primary: Treat underlying disease — anaemia often partially resolves
  • CKD anaemia: Erythropoiesis-stimulating agents (ESA — darbepoetin alfa, epoetin) if Hgb <10 g/dL and GFR <60; target Hgb 10–12 g/dL (avoid >13)
  • Iron supplementation: IV iron preferred if ferritin <100 µg/L or transferrin sat <20% in CKD on ESA
  • Transfusion: Reserve for symptomatic patients or Hgb <7–8 g/dL; each unit packed RBCs raises Hgb ~1 g/dL
ESA risks: Hypertension, thromboembolism, potential tumour growth — avoid in malignancy unless palliative/chemotherapy-related anaemia.

Haemolysis Indicator Calculator

Enter available values to estimate haemolysis probability and guide next investigations.

Sickle Cell Disease — Pathophysiology & GCC Prevalence

Molecular Basis

Point mutation in beta-globin gene (Glu→Val at position 6) → HbS. Under deoxygenation, HbS polymerises → sickle-shaped erythrocytes → vaso-occlusion, haemolysis, endothelial activation, multi-organ ischaemia.

Genotypes

GenotypeConditionSeverity
HbASSickle cell trait (carrier)Usually asymptomatic
HbSSSickle cell disease (SCA)Severe
HbSCSC diseaseModerate
HbS/beta-thalSickle-beta thalassaemiaVariable

GCC Prevalence

Very high burden in GCC:

Saudi Arabia: sickle cell trait 4–8% (highest in Eastern Province — up to 17% in Qatif/Al-Ahsa). Bahrain: ~2–3% trait. UAE: significant burden among local nationals and African/South Asian expats. Oman, Qatar, Kuwait: notable prevalence. Predominantly affects Saudi nationals, Bahraini, and communities with African ancestry.

Common Crisis Triggers

  • Infection (most common — vaccinate against Streptococcus pneumoniae, meningococcus, Haemophilus)
  • Dehydration — especially in GCC heat
  • Cold exposure, temperature change (air conditioning)
  • Hypoxia (altitude, flying, surgery)
  • Physical/emotional stress, fatigue
  • Alcohol, smoking

Vaso-Occlusive (Pain) Crisis Management

Assessment

  • Pain score (NRS 0–10), location, duration, character
  • Vital signs — fever may indicate sepsis/ACS
  • O2 saturation — target >95% (patient's baseline)
  • FBC, reticulocytes (aplastic crisis if retics fall), blood cultures if febrile
  • Chest X-ray if respiratory symptoms

Analgesia Ladder

Step 1: NSAIDs (ibuprofen/diclofenac) + paracetamol — if not contraindicated (renal function).
Step 2: Oral weak opioid (codeine, tramadol).
Step 3: IV/SC morphine or IV PCA (patient-controlled analgesia). Titrate to pain control.
Note: Many patients have opioid tolerance — use their established dose; avoid undertreating.

Hydration

  • Encourage oral fluids — 3–4L/day if tolerated
  • IV fluids if vomiting or unable to drink: 0.9% NaCl or Hartmann's 2–3L/day
  • Avoid excessive hypotonic fluids (risk of haemolysis)

Supportive Care

  • Warmth — warm packs to painful joints
  • Incentive spirometry — prevents atelectasis/ACS
  • Thromboprophylaxis (LMWH) if admitted
  • Antibiotics (amoxicillin/clavulanate or ceftriaxone) if febrile — functional asplenia
  • Folic acid 5mg daily (ongoing)
Functional asplenia: All SCD patients are functionally asplenic from childhood — susceptible to encapsulated organism sepsis. Penicillin V prophylaxis in children; vaccinations lifelong.

Acute Chest Syndrome (ACS)

EMERGENCY — leading cause of SCD mortality

Definition: New pulmonary infiltrate on CXR + at least one of: fever, chest pain, cough, hypoxia, new respiratory symptoms.

Immediate Management

  • Oxygen: High-flow O2 to maintain SpO2 >95%
  • Analgesia: IV morphine — pain splinting worsens ventilation
  • Incentive spirometry every 2h
  • Antibiotics: Ceftriaxone + azithromycin (atypical coverage)
  • Bronchodilators: If wheeze (salbutamol nebulisation)
  • IV hydration: Cautious — avoid fluid overload

Transfusion Decisions

  • Simple transfusion: If Hgb falls >1 g/dL below baseline or SpO2 deteriorates — target Hgb ~10 g/dL
  • Exchange transfusion: Severe ACS, rapidly deteriorating, SpO2 <90% despite O2, bilateral infiltrates — reduce HbS to <30%
  • Involve haematology immediately
  • HDU/ICU if intubation risk
Hyperviscosity risk: Avoid raising Hgb above 10–11 g/dL with simple transfusion — can increase viscosity and worsen outcome.

Stroke & TCD Screening

  • Children with SCD have ~10% lifetime risk of overt stroke
  • Transcranial Doppler (TCD): Annual screening from age 2–16; high velocity (>200 cm/s) = high risk
  • High-risk children: chronic transfusion programme every 4–6 weeks — reduces stroke risk by ~90%
  • Acute stroke: Urgent exchange transfusion + CT/MRI; thrombolysis generally avoided
  • Chronic programme: Target HbS <30%; iron chelation needed (risk of transfusion iron overload)

Hydroxyurea (Hydroxycarbamide)

  • Mechanism: Increases HbF (fetal Hb) → reduces HbS polymerisation
  • Benefits: Reduces painful crises by ~50%, ACS, hospitalisations, stroke risk, mortality
  • Indicated in: Moderate-severe SCD, ≥3 crises/year, ACS history, stroke, organ damage
  • Dose: 15–35 mg/kg/day oral, titrated to response/toxicity
  • Monitor: FBC 4-weekly — withhold if neutrophils <2.0×10⁹/L or platelets <80×10⁹/L
  • GCC availability: Available at major centres (King Faisal Specialist Hospital, Riyadh; Sheikh Khalifa Medical City); access improving across region
  • Contraindicated in pregnancy — teratogenic; counsel regarding contraception
Gene therapy: Curative strategies (lentiviral gene addition, CRISPR-Cas9 BCL11A erythroid enhancer — betibeglogene/exa-cel) emerging; available at select international centres; GCC patients increasingly being referred.

Thalassaemia — Classification Overview

Alpha Thalassaemia (HBA1/HBA2 deletions)

Genes deletedConditionClinical
1 (α/αα)Silent carrierAsymptomatic, normal MCV
2 (αα/-- or α-/α-)Alpha thal traitMild microcytosis, normal Hgb
3 (α-/--)HbH diseaseModerate haemolytic anaemia, splenomegaly
4 (--/--)Hydrops fetalisIncompatible with life (Hgb Bart's)

Beta Thalassaemia

GenotypeConditionClinical
Beta+/normal or Beta0/normalThal trait (minor)Mild anaemia, very low MCV, HbA2 >3.5%
Beta+/Beta+ or Beta+/Beta0Thal intermediaModerate anaemia; may not be transfusion-dependent
Beta0/Beta0Thal major (Cooley's)Severe — transfusion dependent from 6–24 months
Key diagnostic test: HbA2 >3.5% on HPLC is diagnostic for beta thalassaemia trait. MCV <70 fL with normal ferritin in a GCC patient should prompt haemoglobin electrophoresis.

Beta Thalassaemia Major — Transfusion Programme

Transfusion Protocol

  • Frequency: Every 3–5 weeks (typically 3-weekly)
  • Pre-transfusion Hgb target: ≥9–10 g/dL
  • Post-transfusion target: ~14–15 g/dL (not >15)
  • Leuco-depleted, irradiated blood (prevent allo-immunisation and transfusion-associated GVHD)
  • Full extended red cell phenotype (Rh, Kell) matching preferred
  • Check for new allo-antibodies before each transfusion

Complications of Chronic Transfusion

  • Iron overload — in every organ (liver, heart, endocrine)
  • Allo-immunisation
  • Transfusion reactions
  • Infection transmission (rare with modern screening)
  • Hypersplenism (increased transfusion requirement)

Monitoring Iron Overload

Cardiac iron — T2* MRI: T2* <20 ms = iron loading; T2* <10 ms = severe cardiac iron — high risk of arrhythmia/heart failure. Annual cardiac MRI from age 6–10.
  • LIC (Liver Iron Concentration): MRI R2* (FerriScan) — target <7 mg Fe/g dry weight
  • Serum ferritin: Monitor trend (target <1000 µg/L on chelation); imperfect marker
  • Endocrine function annually: growth, thyroid, glucose, puberty, bone density
  • Liver function (hepatic siderosis → fibrosis → cirrhosis)
  • Echocardiography + 24h ECG if cardiac symptoms

Iron Chelation Therapy

Deferoxamine (Desferal) SC/IV

Subcutaneous infusion via pump over 8–12h, 5–7 nights/week. Dose: 20–50 mg/kg/day SC. IV infusion during transfusion also used. Side effects: local site reactions, growth retardation (high dose in young children), auditory/ocular toxicity — annual audiometry and ophthalmology. Most effective agent but poor adherence due to infusion burden.

Deferasirox (Exjade/Jadenu) Oral

Once-daily oral tablet/granules (with light meal). Dose: 14–28 mg/kg/day. Monitor: serum creatinine, eGFR, urine protein, LFTs monthly initially (risk of renal tubular dysfunction and hepatotoxicity). Do NOT use if eGFR <40. Improves adherence vs deferoxamine. GCC availability: widely used across region.

Deferiprone (Ferriprox) Oral

Three times daily oral. Dose: 75–100 mg/kg/day. Particularly effective for cardiac iron. RISK: Agranulocytosis (1–2%) — weekly FBC monitoring mandatory; stop immediately if neutrophils <1.5×10⁹/L. Also: arthropathy, zinc deficiency. Often used in combination with deferoxamine for severe iron overload.

Haematopoietic Stem Cell Transplant (HSCT): Only curative treatment for thalassaemia major. Best outcomes in young patients (<14 years), class I/II (no hepatomegaly/portal fibrosis, good chelation). Matched sibling donor preferred; matched unrelated donor increasing. GCC national programmes (King Faisal Specialist Hospital Riyadh, Sheikh Khalifa Medical City Abu Dhabi) offer HSCT. Gene therapy (betibeglogene — Zynteglo) emerging as alternative to HSCT.

Thalassaemia Carrier Risk Calculator

Select parent carrier statuses to calculate offspring risk for beta or alpha thalassaemia outcomes.

Haemophilia A & B

Classification

  • Haemophilia A: Factor VIII deficiency (X-linked recessive)
  • Haemophilia B: Factor IX deficiency (X-linked recessive) — "Christmas disease"
  • Affects males; females are carriers (may have reduced levels)
Mild >5%
Moderate 1–5%
Severe <1%
SeverityFactor LevelBleeding Pattern
Mild>5% (>0.05 IU/mL)Post-surgical/trauma only
Moderate1–5%Spontaneous + post-trauma
Severe<1%Spontaneous joint/muscle bleeds

Haemarthrosis Management (RICE + Factor)

Target joint time: Factor replacement within 2 hours of bleed onset significantly reduces joint damage.
RICE: Rest, Ice (wrapped — not directly on skin), Compression (light), Elevation.
Avoid: Aspirin, NSAIDs, IM injections, arterial blood gas (use radial approach with prolonged pressure if essential).

Factor Replacement

  • Haemophilia A: Recombinant Factor VIII (rFVIII) or plasma-derived FVIII
  • Haemophilia B: Recombinant Factor IX (rFIX) or plasma-derived FIX
  • Dose: see formulae (each unit/kg FVIII raises level ~2%; FIX ~1%)
  • Target: minor bleed 30–50%, major bleed/surgery 80–100%
  • Inhibitors: check if poor response — Bethesda assay; use bypassing agents (aPCC/rFVIIa)
Prophylaxis (severe disease): Regular factor infusions 2–3×/week (FVIII) or 1–2×/week (FIX) prevent joint damage. Extended half-life products allow less frequent dosing. Emicizumab (subcutaneous bispecific antibody) — approved for Haemophilia A (with or without inhibitors).

GCC availability: Factor concentrates available at haemophilia centres (King Faisal Specialist Hospital Riyadh — largest MENA haemophilia centre; Hamad Medical Corp Qatar; Cleveland Clinic Abu Dhabi). Access varies for newer products (emicizumab, gene therapy).

Von Willebrand Disease (VWD)

Most common inherited bleeding disorder (~1% population); autosomal dominant (types 1/2) or recessive (type 3).

TypeDefectPrevalence
Type 1Partial quantitative deficiency of VWF70–80%
Type 2Qualitative defects (2A, 2B, 2M, 2N)15–20%
Type 3Complete absence of VWFRare, severe

Diagnosis

  • VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo), Factor VIII level
  • PFA-100 (platelet function analyser) — useful screening
  • Multimer analysis for type 2

Treatment

  • Desmopressin (DDAVP): Type 1 — releases endogenous VWF; IV/intranasal; test dose first; risk of hyponatraemia (restrict fluids 24h post-dose)
  • VWF concentrate: Types 2 & 3, surgical procedures, DDAVP failure
  • Tranexamic acid: Adjunct for mucosal bleeds (dental, menorrhagia)

Immune Thrombocytopenia (ITP)

Platelet count <100×10⁹/L with no identifiable secondary cause. Autoimmune platelet destruction (anti-GPIIb/IIIa antibodies) + impaired thrombopoiesis.

Treatment Ladder

First line: Prednisolone 1 mg/kg/day × 2–4 weeks (taper); or IVIG 1g/kg × 1–2 days (rapid response needed).
Second line: Thrombopoietin receptor agonists (TPO-RA): eltrombopag (oral) or romiplostim (SC weekly). Rituximab (anti-CD20). Azathioprine, MMF.
Third line: Splenectomy (durable remission 60–70%). Preceded by vaccinations (pneumococcal, meningococcal, Hib) at least 2 weeks before.

Platelet Transfusion

Do NOT transfuse platelets routinely — rapid destruction. Reserve for life-threatening bleeding (intracranial haemorrhage, major surgery) — transfuse with IVIG simultaneously.

Nursing Precautions

  • Avoid NSAIDs, aspirin, anticoagulants
  • IM injections — use smallest gauge; apply pressure 5 min
  • Bleeding precautions if plt <20×10⁹/L: soft toothbrush, electric razor, avoid contact sports
  • Plt <10×10⁹/L: prophylactic platelet transfusion threshold (unless ITP)

Antiplatelet Medications in Surgical Patients

DrugMechanismPre-op Stop TimeReversal
AspirinCOX-1 inhibition (irreversible)7 days (if not cardiac stent — often continue)Platelet transfusion (1 adult dose)
ClopidogrelP2Y12 inhibitor (irreversible)5–7 daysPlatelet transfusion
TicagrelorP2Y12 inhibitor (reversible)3–5 daysPlatelet transfusion + ticagrelor washout
PrasugrelP2Y12 inhibitor (irreversible)7 daysPlatelet transfusion
Dual antiplatelet therapy (DAPT) within 12 months of coronary stent: Do NOT stop without cardiology consultation — risk of in-stent thrombosis and myocardial infarction.

Inherited Thrombophilias

ConditionMechanismVTE Risk (relative)GCC Note
Factor V Leiden (FVL)Resistance to activated protein C; FV R506Q mutationHeterozygous ×4–8; Homozygous ×80GCC consanguinity → higher homozygous rates
Prothrombin G20210AElevated prothrombin → excess thrombinHeterozygous ×3Found in Arab populations; compound heterozygotes with FVL
Protein C deficiencyReduced anticoagulant activity×3–15Consanguinity → severe homozygous neonatal purpura fulminans
Protein S deficiencyReduced cofactor for APC×2–10Type I/II/III; pregnancy further reduces PS levels
Antithrombin III deficiencyReduced thrombin/Xa inhibition×10–20Most thrombogenic — heparin resistance
GCC consanguinity: Rates of first-cousin marriage in GCC are among the highest globally (20–40% in some regions). This significantly increases the risk of homozygous autosomal recessive thrombophilia states (homozygous Protein C/S deficiency, ATIII deficiency) which can present dramatically in neonates. Genetic counselling is essential.

Testing Caveats

Antiphospholipid Syndrome (APS)

Diagnosis (Sapporo Criteria)

Clinical: Arterial or venous thrombosis, OR pregnancy morbidity (3+ miscarriages, intrauterine death >10w, premature birth <34w due to placental insufficiency)

Laboratory (positive twice, 12 weeks apart):

  • Lupus anticoagulant (LA)
  • Anticardiolipin IgG or IgM >40 GPL/MPL units
  • Anti-beta2-glycoprotein I IgG or IgM

Primary vs Secondary

  • Primary APS: No underlying connective tissue disease
  • Secondary APS: Associated with SLE (most common), other autoimmune disease

Treatment

Venous thrombosis: Warfarin long-term; target INR 2.0–3.0. DOACs may be used in triple-negative or low-risk APS but warfarin preferred for triple-positive.
Arterial thrombosis / recurrent thrombosis: Warfarin target INR 2.5–3.5 + consider low-dose aspirin.
Obstetric APS: Low-dose aspirin + LMWH from BFP until 6 weeks postpartum.
Catastrophic APS (CAPS): Rare, life-threatening — thrombosis in ≥3 organs within 1 week. Triple therapy: anticoagulation + corticosteroids + IVIG or plasma exchange. Mortality 50% despite treatment.

Disseminated Intravascular Coagulation (DIC)

Pathophysiology

Massive simultaneous activation of coagulation and fibrinolysis → consumption of clotting factors and platelets → bleeding AND microvascular thrombosis simultaneously.

Common Triggers in GCC

  • Sepsis (Gram-negative most common) — most frequent cause
  • Obstetric catastrophe: Abruption, IUFD, amniotic fluid embolism, HELLP
  • Trauma: Major trauma, burns
  • Malignancy: AML (esp M3/APL), metastatic solid tumours
  • Transfusion reactions, snake envenomation

Laboratory Features

  • Prolonged PT, APTT
  • Low fibrinogen (<1.5 g/L — severe)
  • Elevated D-dimer (very high)
  • Thrombocytopenia (falling trend)
  • Microangiopathic haemolytic anaemia on film (schistocytes)

Management Principles

Priority 1 — Treat the underlying cause: DIC will not resolve without treating sepsis (antibiotics), delivering baby (obstetric cause), etc.
Replace consumed factors:
FFP 15 mL/kg — for PT/APTT prolongation + active bleeding
Cryoprecipitate — if fibrinogen <1.5 g/L (contains fibrinogen, FVIII, VWF, FXIII)
Platelet transfusion — if plt <50 + bleeding (or <20 prophylactically)
Vitamin K IV — if liver disease component
Heparin in DIC: NOT routinely recommended. Consider ONLY in thrombosis-dominant DIC (purpura fulminans, APML, large vessel thrombosis) — specialist decision only.

Massive Haemorrhage Protocol (MHP)

1:1:1 ratio: Packed RBCs : FFP : Platelets (e.g. 6:6:1 pool)
Tranexamic acid (TXA): 1g IV over 10 min within 3h of trauma (CRASH-2) — reduces mortality; also in PPH (WOMAN trial). Antifibrinolytic — reduces clot breakdown.

Blood Disorder Burden in GCC Nations

CountrySCD TraitBeta-Thal TraitKey Population
Saudi Arabia4–8% (up to 17% in Eastern Province)3–4%Saudi nationals; Eastern Province highest burden
Bahrain~2–3%~2%Bahraini nationals
UAE~2%~3%Emirati nationals; South Asian expats (beta-thal)
Qatar~1.5%~1–2%Qatari nationals
Kuwait~3%~2%Kuwaiti nationals
Oman~6%~2%Omani nationals; Mediterranean/South Asian thal
Alpha thalassaemia: Also prevalent across GCC — often undiagnosed as HbA2 is normal. Southeast Asian and South Asian expats carry high rates of alpha thalassaemia (--SEA deletion). Important in obstetric context (Hgb Bart's hydrops fetalis).

Neonatal & Premarital Screening

Neonatal Screening Programmes

  • Saudi Arabia: Mandatory expanded neonatal screening includes SCD, G6PD, hypothyroidism, PKU, and other IEMs — all newborns screened via heel-prick
  • UAE: National newborn screening (haemoglobinopathies, metabolic disorders)
  • Qatar: National newborn screening programme
  • Kuwait, Bahrain, Oman: National haemoglobinopathy screening programmes

Premarital Genetic Screening

Saudi Arabia (mandatory since 2004): Haemoglobinopathy (SCD, thalassaemia) and infectious disease screening (HIV, HBV, HCV) before marriage. Results disclosed to couple with genetic counselling. Marriage not legally prevented but couples counselled on risks. Aim: prevent thalassaemia major births through informed decisions.
  • UAE: Mandatory premarital screening since 2008 — similar scope
  • Bahrain, Kuwait, Oman, Qatar: Premarital screening available; varying degrees of mandate
  • Genetic counsellors integral to these programmes

Blood Donation & Cultural Considerations

Blood Donation Patterns in GCC

  • GCC relies heavily on expat voluntary donors (South Asian, Filipino, other Asian communities) — strong voluntary donation culture
  • National donation rates increasing with awareness campaigns (Ramadan blood drives)
  • Blood safety: NAT (nucleic acid testing) testing standard in all GCC national blood banks
  • Family replacement donation still occurs in some settings — being phased out in favour of voluntary donation

Jehovah's Witness Patients

Right to refuse: Competent adult Jehovah's Witness patients have the legal and ethical right to refuse blood transfusion — even life-saving. Nurses must document informed refusal carefully. Advance directive / advance care planning essential pre-operatively.
Bloodless surgery programmes available in GCC:
  • Cleveland Clinic Abu Dhabi — dedicated bloodless medicine & surgery programme
  • Sheikh Khalifa Medical City (SKMC) Abu Dhabi
  • Techniques: intraoperative cell salvage, acute normovolaemic haemodilution, iron optimisation pre-op, EPO, antifibrinolytics (TXA)

Specialist Haematology Centres in GCC

Sickle Cell Comprehensive Care Centres

  • King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh: Largest haematology/haemophilia centre in MENA; SCD programme including hydroxyurea, chronic transfusion, stem cell transplant, gene therapy referral
  • Maternity & Children's Hospital, Dammam: Eastern Province SCD burden — major paediatric SCD programme
  • Salmaniya Medical Complex, Bahrain: National SCD programme
  • Sultan Qaboos University Hospital, Muscat: Oman SCD/thalassaemia programme

Thalassaemia & Haemophilia Centres

  • KFSH&RC Riyadh: Largest haemophilia centre in MENA; national haemophilia registry; BMT programme for thalassaemia
  • Al Ain Hospital / Tawam Hospital, UAE: Thalassaemia day care unit
  • Hamad Medical Corporation, Qatar: National haematology programme
  • Kuwait Cancer Control Centre: Haematology including benign disorders

Telehaematology & Outreach

  • Remote/rural areas in Saudi Arabia, Oman: telemedicine haematology consultations growing
  • National registries for haemophilia (Saudi Haemophilia Registry) and thalassaemia
  • GCC Thalassaemia Alliance — regional cooperation on screening and treatment

G6PD Deficiency — GCC Note

Glucose-6-phosphate dehydrogenase deficiency is highly prevalent in GCC (especially Saudi Arabia, Bahrain, Iraq-origin populations). X-linked; males affected most severely.

Clinical Presentation

  • Neonatal jaundice (common presentation — neonatal screening detects most cases)
  • Acute haemolytic anaemia triggered by: primaquine, dapsone, rasburicase, nitrofurantoin, high-dose aspirin, fava beans, infection, methylene blue
  • Chronic non-spherocytic haemolytic anaemia (CNSHA) — severe variants (Class I)

Nursing Considerations

  • Check G6PD status before prescribing oxidant drugs — especially primaquine (malaria treatment/prophylaxis), dapsone
  • Rasburicase (for tumour lysis) absolutely contraindicated in G6PD deficiency — severe acute haemolysis
  • Educate patients to avoid fava beans and relevant medications
  • Treatment of acute haemolysis: remove trigger, supportive care, blood transfusion if severe; haemolysis usually self-limiting once trigger removed

Practice MCQs — Benign Blood Disorders (GCC Nursing)

Q1.A 28-year-old Bahraini woman presents with Hgb 8.5 g/dL, MCV 65 fL, ferritin 8 µg/L, and transferrin saturation 10%. She is most likely to have:
Q2.When counselling a patient about oral iron supplementation, which instruction is most important to improve absorption?
Q3.A 12-year-old Saudi boy with sickle cell disease develops sudden onset chest pain, cough, fever 38.5°C, and SpO2 88% on room air. CXR shows a new left lower lobe infiltrate. What is the priority intervention?
Q4.A beta thalassaemia major patient on deferiprone reports her absolute neutrophil count is 1.2×10⁹/L. What is the correct nursing action?
Q5.A patient with ITP (platelet count 18×10⁹/L) is admitted for IV methylprednisolone. She develops a severe headache with neck stiffness. Which action is most appropriate?
Q6.Which statement about sickle cell disease and hydroxyurea is correct?
Q7.A newly diagnosed pernicious anaemia patient asks why she needs intramuscular injections instead of oral B12 tablets. What is the best explanation?
Q8.In disseminated intravascular coagulation (DIC) secondary to Gram-negative sepsis, what is the most important initial management step?
Q9.Both parents are confirmed beta thalassaemia trait carriers. What is the risk with each pregnancy of having a child with beta thalassaemia major?
Q10.A patient with antiphospholipid syndrome had an arterial stroke 3 months ago. He is on warfarin. What is the correct INR target?
0/10

GCC Nurse Benign Blood Disorders Guide — For educational purposes. Always follow local clinical guidelines, institutional protocols, and consult the haematology team for individual patient management. Updated April 2026.